Amarin Corp Plc (AMRN)

[Whalatane]

Chas Interesting presentation thx

I would challenge the following

The second concern stems from the lower statin dose for JELIS. Following JL’s point that much of the statin benefit derives from its anti-inflammatory properties (see JUPITER), one could argue that the additional statin in both arms of RI could mitigate some of the inflammation, leaving less for V to mitigate and reducing RRR for RI due to diminishing returns of anti-inflammatory action. This concern is reduced for me by the fact that JELIS showed that raising even an already quite high EPA level has substantial benefits that persist across subgroups

my comment re " This concern is reduced for me etc "
They were on simavastatin in JELIS . Many /most will be on generic Lipitor and maybe some on Crestor in R-IT .... both are stronger Statins then Sima and the patients are probably on higher doses......enough to get their mean LDL probably closer to 90 ....ie half that of the mean LDL levels in the JELIS secondary subgroup.

So while I agree that raising already high EPA levels has substantial benefits .....in JELIS 2ndry its against low dose Simavastatin with an LDL mean of 178 ......not against stronger Statins with a mean LDL closer to 90.
I don't think you extrapolate benefit to the degree you do .


JMO ...always interesting to read your posts
Kiwi